Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

EIP Pharma, Inc.

  • John Alam, EIP Pharma

EIP Pharma Inc. is a clinical-stage biopharmaceutical company focused on the development & commercialization of innovative drug treatments for Alzheimer’s disease (AD) and other central neurologic disorders. Our lead product candidate, neflamapimod, is a novel oral small molecule drug that inhibits the intra-cellular enzyme p38 mitogen-activated protein kinase alpha. The company was launched in 2014 by industry R&D leaders and has assembled a highly experienced executive management team, board of directors and scientific advisory board to execute on its mission.

Based on positive preclinical and phase 2a clinical trial results, in March 2018 the company initiated a Phase 2b randomized double-blind placebo-controlled clinical study of neflamapimod in subjects with early AD, which is called REVERSE-SD; the results of which are expected in the second half of 2019. The REVERSE-SD study is fully funded through a $20.5M Series B financing round completed in April 2018.

  • Date:Tuesday, February 12
  • Time:10:00 AM - 10:15 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Submission ID:23313
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Introduce the company and our innovative approach to treat Alzheimer's associated memory deficits
  • Company Website:www.eipppharma.com
  • Company HQ City:Cambridge MA
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$26.7M
  • Size of Last Investment Round:$20.5M
  • Previous and Current Investors:Individual investors (primarily senior biotech executives), Access Industries
  • CEO/Top Company Official:John Alam
  • Year Founded:2014
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:Neflamapimod
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):1
  • Additional Information/Comments:Neflamapimod is the most clinically advanced investigational drug that targets intra-neuronal molecular pathways that lead to memory deficits in AD. EIP Pharma licensed neflamapimod from Vertex Pharmaceuticals in 2014. At Vertex, the therapy had completed a full chronic toxicology program and demonstrated significant clinical activity in a phase 2a study in rheumatoid arthritis. EIP Pharma conducted additional preclinical studies that demonstrated neflamapimod reversed functional deficits in CNS animal models of CNS disease, which combined with the prior development experience allowed the company to go directly to phase 2a clinical trials in patients with AD. The phase 2a results demonstrated statistically significant improvements versus baseline in tests of episodic memory, as well as a target engagement. The results on an ongoing Phase 2b randomized double-blind placebo-controlled clinical study of neflamapimod in subjects with early AD are expected in the second half of 2019.
Speakers
John Alam
EIP Pharma
Back